Uso de Bupropiona para Tratamento do Transtorno de Déficit de Atenção/Hiperatividade (TDAH)
##plugins.themes.bootstrap3.article.sidebar##
Publicado
Jul 9, 2023
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Identificar na literatura evidências para uso da bupropiona no tratamento do transtorno do déficit de atenção com hiperatividade (TDAH). Métodos: Revisão integrativa da literatura, utilizando artigos publicados entre 1990 e 2022, no idioma inglês, espanhol ou português com texto completo disponível. Teve como questão norteadora: Há evidências para o uso da bupropiona no tratamento de TDAH? A seleção dos descritores universais a serem empregados foi através de consulta aos Descritores em Ciências da Saúde (DeCS) e do Medical Subject Headings (MeSH), sendo definidos os descritores em inglês (Bupropion, Attention Deficit Disorder with Hyperactivity e Drug Therapy), espanhol (Bupropión, Trastorno por Déficit de Atención con Hiperactividad e Quimioterapia) e português (Bupropiona, Transtorno do Deficit de Atenção com Hiperatividade e Tratamento Farmacológico), realizando combinações dos termos com o operador booleano “AND”. Resultados: 21 artigos cumpriram os critérios de inclusão/exclusão e foram utilizados no estudo. Estes apresentam dados gerais relativos à eficácia, segurança e uso da bupropiona direto ou indiretamente avaliada frente aos psicoestimulantes para tratar TDAH. Considerações finais: Apesar dos resultados conflitantes na literatura, a bupropiona pode ser uma alternativa de tratamento para o TDAH em indivíduos com características específicas.
##plugins.themes.bootstrap3.article.details##
Como Citar
ProcópioJ. V. V., BaltazarB. T., FidelisG. P., GomesF. W. C., LacerdaM. V. L. B., GomesC. H. F. de M., MoreiraA. F. C. M., FeitosaA. do N. A., AbreuH. M. B. F., & NetoM. C. de B. (2023). Uso de Bupropiona para Tratamento do Transtorno de Déficit de Atenção/Hiperatividade (TDAH). Revista Eletrônica Acervo Saúde, 23(7), e13173. https://doi.org/10.25248/reas.e13173.2023
Seção
Revisão Bibliográfica
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
1. AMERICAN PSYCHIATRIC ASSOCIATION. Manual diagnóstico e estatístico de transtornos mentais. 5. ed. Porto Alegre: Artmed, 2014.
2. BARNARD-BRAK L, et al. Medication Non-Adherence and Tolerance Breaks Among Adolescents and Young Adults With ADHD. Journal Of Attention Disorders, 2023; 00(0): e108705472311675.
3. BARRICKMAN LL, et al. Bupropion versus Methylphenidate in the Treatment of Attention-Deficit Hyperactivity Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry, 1995; 34(5): 649-657.
4. CABRAL MDI, et al. Attention-deficit/hyperactivity disorder: diagnostic criteria, epidemiology, risk factors and evaluation in youth. Translational Pediatrics, 2020; 9(1): 104-113.
5. CÂNDIDO RCF, et al. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews, 2021; 2021(1): 1-86.
6. CONNERS CK, et al. Bupropion Hydrochloride in Attention Deficit Disorder with Hyperactivity. Journal Of The American Academy Of Child & Adolescent Psychiatry, 1996; 35(10): 1314-1321.
7. DAVISS WB, et al. Bupropion Sustained Release in Adolescents With Comorbid Attention-Deficit/Hyperactivity Disorder and Depression. Journal Of The American Academy Of Child & Adolescent Psychiatry, 2001; 40(3): 307-314.
8. ELLIOTT J, et al. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: a systematic review and network meta-analysis. Plos One, 2020; 15(10): 0240584-0240584.
9. FARAONE SV, et al. Attention-deficit/hyperactivity disorder. Nature Reviews Disease Primers, 2015; 1(1): 1-23.
10. FARAONE SV e GLATT SJ. A Comparison of the Efficacy of Medications for Adult Attention-Deficit/Hyperactivity Disorder Using Meta-Analysis of Effect Sizes. The Journal Of Clinical Psychiatry, 2009; 71(06): 754-763.
11. FRANK E, et al. Examining Why Patients With Attention-Deficit/Hyperactivity Disorder Lack Adherence to Medication Over the Long-Term. The Journal Of Clinical Psychiatry, 2015; 76(11): 1459-1468.
12. GNANAVEL S, et al. Attention deficit hyperactivity disorder and comorbidity: a review of literature. World Journal Of Clinical Cases, 2019; 7(17): 2420-2426.
13. JAFARINIA M, et al. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. Human Psychopharmacology: Clinical and Experimental, 2012; 27(4): 411-418.
14. KAMIMURA-NISHIMURA KI, et al. Strategies for improving ADHD medication adherence. Current Psychiatry, 2019; 18(8): 25-38.
15. KHAN MU e ASLANI P. Exploring factors influencing medication adherence from initiation to discontinuation in parents and adolescents with attention deficit hyperactivity disorder. Clinical Pediatrics, 2020; 59(3): 285-296.
16. KUPERMAN S, et al. Bupropion SR vs. Methylphenidate vs. Placebo for Attention Deficit Hyperactivity Disorder in Adults. Annals Of Clinical Psychiatry, 2001; 13(3): 129-134.
17. LARANJEIRA C, et al. Therapeutic Adherence of People with Mental Disorders: an evolutionary concept analysis. International Journal Of Environmental Research And Public Health, 2023; 20(5): 3869.
18. LEVIN FR, et al. Bupropion Treatment for Cocaine Abuse and Adult Attention-Deficit/Hyperactivity Disorder. Journal Of Addictive Diseases, 2002; 21(2): 1-16.
19. MANEETON N., et al. Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. Psychiatry And Clinical Neurosciences, 2011; 65(7): 611-617.
20. MOSHEVA M, et al. Pharmacotherapy of attention-deficit hyperactivity disorder: common quandaries, dilemmas and challenges. International Clinical Psychopharmacology, 2020; 35(6): 300-304.
21. NAGLICH AC, et al. Systematic review of preclinical, clinical, and post-marketing evidence of bupropion misuse potential. The American Journal of Drug And Alcohol Abuse, 2019; 45(4): 341-354.
22. NAZAROVA VA, et al. Treatment of ADHD: drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Frontiers In Pharmacology, 2022; 13: 1-19.
23. NG QX. A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Journal Of Child And Adolescent Psychopharmacology, 2017; 27(2): 112-116.
24. PADILHA SCOS, et al. Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis. European Child & Adolescent Psychiatry, 2018; 27(10): 1335-1345.
25. PETERSON K, et al. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology, 2007; 197(1): 1-11.
26. RIGGS PD, et al. An Open Trial of Bupropion for ADHD in Adolescents With Substance Use Disorders and Conduct Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry, 1998; 37(12): 1271-1278.
27. SCHEIN J, et al. Reasons for treatment changes in adults with attention-deficit/hyperactivity disorder: a chart review study. Bmc Psychiatry, 2022; 22(1): 1-11.
28. SEGENREICH D e MATTOS P. Eficácia da bupropiona no tratamento do TDAH: uma revisão sistemática e análise crítica de evidências. Archives Of Clinical Psychiatry (São Paulo), 2004; 31(3): 117-123.
29. SEO J-C, et al. Prevalence and Comorbidities of Attention Deficit Hyperactivity Disorder Among Adults and Children/Adolescents in Korea. Clinical Psychopharmacology And Neuroscience, 2022; 20(1): 126-134.
30. STAHL SM, et al. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. The Primary Care Companion For Cns Disorders, 2004; 6(4): 159-166.
31. TORONTO CE e REMINGTON R (ed.). A Step-by-Step Guide to Conducting an Integrative Review. Cham/ CHE: Springer Nature Switzerland AG, 2020.
32. VERBEECK W, et al. Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review. Advances In Therapy, 2009; 26(2): 170-184.
33. WILENS T, et al. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biological Psychiatry, 2003; 54(1): 9-16.
34. WILENS TE, et al. A Controlled Clinical Trial of Bupropion for Attention Deficit Hyperactivity Disorder in Adults. American Journal Of Psychiatry, 2001; 158(2): 282-288.
35. WENDER PH e REIMHERR FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. American Journal of Psychiatry, 1990; 147(8): 1018-1020.
2. BARNARD-BRAK L, et al. Medication Non-Adherence and Tolerance Breaks Among Adolescents and Young Adults With ADHD. Journal Of Attention Disorders, 2023; 00(0): e108705472311675.
3. BARRICKMAN LL, et al. Bupropion versus Methylphenidate in the Treatment of Attention-Deficit Hyperactivity Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry, 1995; 34(5): 649-657.
4. CABRAL MDI, et al. Attention-deficit/hyperactivity disorder: diagnostic criteria, epidemiology, risk factors and evaluation in youth. Translational Pediatrics, 2020; 9(1): 104-113.
5. CÂNDIDO RCF, et al. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews, 2021; 2021(1): 1-86.
6. CONNERS CK, et al. Bupropion Hydrochloride in Attention Deficit Disorder with Hyperactivity. Journal Of The American Academy Of Child & Adolescent Psychiatry, 1996; 35(10): 1314-1321.
7. DAVISS WB, et al. Bupropion Sustained Release in Adolescents With Comorbid Attention-Deficit/Hyperactivity Disorder and Depression. Journal Of The American Academy Of Child & Adolescent Psychiatry, 2001; 40(3): 307-314.
8. ELLIOTT J, et al. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: a systematic review and network meta-analysis. Plos One, 2020; 15(10): 0240584-0240584.
9. FARAONE SV, et al. Attention-deficit/hyperactivity disorder. Nature Reviews Disease Primers, 2015; 1(1): 1-23.
10. FARAONE SV e GLATT SJ. A Comparison of the Efficacy of Medications for Adult Attention-Deficit/Hyperactivity Disorder Using Meta-Analysis of Effect Sizes. The Journal Of Clinical Psychiatry, 2009; 71(06): 754-763.
11. FRANK E, et al. Examining Why Patients With Attention-Deficit/Hyperactivity Disorder Lack Adherence to Medication Over the Long-Term. The Journal Of Clinical Psychiatry, 2015; 76(11): 1459-1468.
12. GNANAVEL S, et al. Attention deficit hyperactivity disorder and comorbidity: a review of literature. World Journal Of Clinical Cases, 2019; 7(17): 2420-2426.
13. JAFARINIA M, et al. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. Human Psychopharmacology: Clinical and Experimental, 2012; 27(4): 411-418.
14. KAMIMURA-NISHIMURA KI, et al. Strategies for improving ADHD medication adherence. Current Psychiatry, 2019; 18(8): 25-38.
15. KHAN MU e ASLANI P. Exploring factors influencing medication adherence from initiation to discontinuation in parents and adolescents with attention deficit hyperactivity disorder. Clinical Pediatrics, 2020; 59(3): 285-296.
16. KUPERMAN S, et al. Bupropion SR vs. Methylphenidate vs. Placebo for Attention Deficit Hyperactivity Disorder in Adults. Annals Of Clinical Psychiatry, 2001; 13(3): 129-134.
17. LARANJEIRA C, et al. Therapeutic Adherence of People with Mental Disorders: an evolutionary concept analysis. International Journal Of Environmental Research And Public Health, 2023; 20(5): 3869.
18. LEVIN FR, et al. Bupropion Treatment for Cocaine Abuse and Adult Attention-Deficit/Hyperactivity Disorder. Journal Of Addictive Diseases, 2002; 21(2): 1-16.
19. MANEETON N., et al. Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. Psychiatry And Clinical Neurosciences, 2011; 65(7): 611-617.
20. MOSHEVA M, et al. Pharmacotherapy of attention-deficit hyperactivity disorder: common quandaries, dilemmas and challenges. International Clinical Psychopharmacology, 2020; 35(6): 300-304.
21. NAGLICH AC, et al. Systematic review of preclinical, clinical, and post-marketing evidence of bupropion misuse potential. The American Journal of Drug And Alcohol Abuse, 2019; 45(4): 341-354.
22. NAZAROVA VA, et al. Treatment of ADHD: drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Frontiers In Pharmacology, 2022; 13: 1-19.
23. NG QX. A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Journal Of Child And Adolescent Psychopharmacology, 2017; 27(2): 112-116.
24. PADILHA SCOS, et al. Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis. European Child & Adolescent Psychiatry, 2018; 27(10): 1335-1345.
25. PETERSON K, et al. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology, 2007; 197(1): 1-11.
26. RIGGS PD, et al. An Open Trial of Bupropion for ADHD in Adolescents With Substance Use Disorders and Conduct Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry, 1998; 37(12): 1271-1278.
27. SCHEIN J, et al. Reasons for treatment changes in adults with attention-deficit/hyperactivity disorder: a chart review study. Bmc Psychiatry, 2022; 22(1): 1-11.
28. SEGENREICH D e MATTOS P. Eficácia da bupropiona no tratamento do TDAH: uma revisão sistemática e análise crítica de evidências. Archives Of Clinical Psychiatry (São Paulo), 2004; 31(3): 117-123.
29. SEO J-C, et al. Prevalence and Comorbidities of Attention Deficit Hyperactivity Disorder Among Adults and Children/Adolescents in Korea. Clinical Psychopharmacology And Neuroscience, 2022; 20(1): 126-134.
30. STAHL SM, et al. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. The Primary Care Companion For Cns Disorders, 2004; 6(4): 159-166.
31. TORONTO CE e REMINGTON R (ed.). A Step-by-Step Guide to Conducting an Integrative Review. Cham/ CHE: Springer Nature Switzerland AG, 2020.
32. VERBEECK W, et al. Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review. Advances In Therapy, 2009; 26(2): 170-184.
33. WILENS T, et al. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biological Psychiatry, 2003; 54(1): 9-16.
34. WILENS TE, et al. A Controlled Clinical Trial of Bupropion for Attention Deficit Hyperactivity Disorder in Adults. American Journal Of Psychiatry, 2001; 158(2): 282-288.
35. WENDER PH e REIMHERR FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. American Journal of Psychiatry, 1990; 147(8): 1018-1020.